PDUFA Date

Otsuka's centanafadine faces July 24 FDA decision for adult ADHD

The priority-review verdict on Otsuka's serotonin-norepinephrine-dopamine reuptake inhibitor rests on two pivotal trials that already met their primary endpoint against placebo.

By AppliedXLJuly 15, 2026Trial NCT03605680

Executive Summary

The FDA is set to decide by July 24, 2026 whether to approve centanafadine, a Phase 3 asset, for adult ADHD, under a priority review that signals the agency already views the efficacy case as adequate to move faster than standard review.
The application rests on twin pivotal trials that both reported hitting their registered primary endpoint against placebo, not a single readout still pending confirmation.
Centanafadine would enter a field of oral small-molecule ADHD therapies with a mechanism combining three reuptake targets at once, a design distinct from single- or dual-target stimulants and non-stimulants already used in the disorder.
The efficacy record is established; what remains open is how the agency weighs the safety database and manufacturing package, factors the trial record itself cannot answer.

The catalyst

Otsuka Pharmaceutical Development & Commercialization, Inc. disclosed a Prescription Drug User Fee Act target action date of July 24, 2026 for centanafadine, its investigational treatment for attention-deficit/hyperactivity disorder in adults. The FDA granted the application priority review, a six-month review clock reserved for applications the agency judges could offer an improvement over existing therapy. Centanafadine is a small molecule that inhibits reuptake at the serotonin, norepinephrine, and dopamine transporters simultaneously, a combined mechanism Otsuka has described as first-in-class among approved ADHD treatments. Otsuka

The evidence behind it

The application draws on two identically designed, randomized, double-blind, placebo-controlled Phase 3 trials, NCT03605680 and NCT03605836, each testing centanafadine sustained-release tablets against placebo in adults with ADHD. NCT03605680 enrolled 604 adults, completed in April 2020, and posted results showing the trial met its registered primary endpoint: change from baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) at Day 42, an 18-item clinician scale scored 0 to 54 where a larger negative change indicates greater symptom improvement. Otsuka's May 2026 disclosure states the registered primary endpoint was met with a statistically significant, clinically meaningful improvement versus placebo across the trial pair. NCT03605680+1

Post hoc detail

Otsuka presented post hoc, exploratory pooled analyses from the two trials at the 2026 American Society of Clinical Psychopharmacology meeting, covering 744 adults split across centanafadine 200 mg (n=242), 400 mg (n=241), and placebo (n=261). Beyond the core AISRS endpoint, centanafadine was associated with improved patient-reported executive function and emotional dysregulation at Week 6, measured on the Adult ADHD Self-Report Scale Expanded Version subscales, areas the company and an investigator, Dr. Lenard A. Adler of NYU Langone Health, described as underaddressed by current ADHD treatments. Because these are post hoc, exploratory measures layered onto an already-positive primary result, they read as supporting context for the label discussion rather than a second confirmatory endpoint. Otsuka

Program scale

Centanafadine's ADHD program spans nine trials, including completed Phase 3 studies in adults, adolescents, and children, and a Phase 3 study in pediatric patients still recruiting. A separate Phase 3b trial testing centanafadine XR 280 mg once daily in ADHD patients with comorbid anxiety also met its primary endpoint on the AISRS scale versus placebo in results Otsuka announced in June 2026, reinforcing the effect seen in the pivotal pair rather than introducing a new signal. NCT03605680

The competitive frame

Direct comparators sharing the serotonin transporter target and small-molecule modality in ADHD include Supernus Pharmaceuticals' viloxazine, in a Phase 4 trial (NCT06185985), and Aytu BioPharma's amphetamine, in a Phase 4 trial (NCT07169162). Both are approved therapies already used in ADHD; centanafadine would need to demonstrate its triple-reuptake mechanism holds up on the same efficacy and tolerability terms these established options have already set, given no single ADHD therapy today combines serotonin, norepinephrine, and dopamine reuptake inhibition in one molecule. The safety data posted for the pivotal trial show no deaths and low rates of serious adverse events across placebo and both centanafadine dose arms, with headache, decreased appetite, and dry mouth as the most common adverse events. NCT03605680

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.